Infront, a leading trading and information solution provider for professional investors, today announced a partnership with RSRCHXchange, to provide its institutional clients with access to the RSRCHX platform, the online marketplace for institutional research.

The partnership makes institutional research, from more than 140 research providers, available on the Infront Terminal from 21 September and will provide Infront clients with a seamless integration between global real-time market information and research published on RSRCHX.

The RSRCHX platform is a research aggregation, procurement and management solution built in consultation with both asset management institutions and research providers to address the challenges of MiFID II compliant research procurement. The RSRCHX platform launched in September 2015; research from over 140 providers is now available to approximately 1000 buy-side firms, and the number is increasing every day.

Morten A. Lindeman, CTO and Co-Founder of Infront, said: “We are pleased to offer our clients a state of the art solution for accessing a marketplace of MiFID II compliant online research. This enables our Infront users to buy research in a more efficient, transparent and auditable way. We see this as an important step in following the future demands on how financial research will be consumed in a post-MiFID II world”.

He added: “Having this great research platform available in the Infront terminal makes it easier for asset managers to access, procure and pay for institutional research and by that potentially adjust investment decisions.”

Jeremy Davies, Co-Founder of RSRCHXchange, said: “We are very excited about the partnership with Infront. What we set out to achieve was to make research easy to find and access from any working environment. Not only will the collaboration make RSRCHX research accessible on the Infront platform; it will also open the research available on our platform to thousands of new users. Infront’s institutional buy-side clients can now access and procure research via one centralised platform. We look forward to working with Infront and their clients in the future.”